Keith Loria

Christel Nielsen, associate professor at Lund University, gathered a team of researchers to find the relationship between tattoo ink exposure and malignant lymphoma and lymphoma subtype risk.

A new study published April 2024 in the JAMA Network looked to establish a link between burn pits and higher respiratory and cardiovascular disease in veterans, responding to widespread concern from veterans.

Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.

Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.

The Choosing Wisely campaign has helped with overscreening and overtreatment. Some experts say better management of end-of-life care and value-based payment would also help steer oncology away from care with poor cost-benefit ratios.

The evidence for active surveillance is stronger, but advances in imaging have improved the ability to distinguish between indolent and aggressive forms of prostate cancer.

Some orthopedic surgeons have been reluctant to perform total hip arthroplasty on people with HIV/AIDS. Researchers at UT Southwestern Medical Center found no additional risks from HIV per se.

The company-sponsored study compared Sunlenca (lenacapavir) with Rukobia (fostemsavir) and Trograzo (ibalizumab).

When addressing errors, researchers focused on the individual who made the error and retraining. Lead author Fatima Laher says attention should be shifted to root cause analysis and process improvement.

University of North Carolina researchers found stable and replication-competent HIV in the microglia in the brain even in people with HIV who had been taking antiretroviral therapy for a long time.

Researchers and clinicians have been wary of treating people living with HIV with Keytruda, Opdivo and other immune checkpoint inhibitors because removing an inhibitory step in the immune response was seen as risky for people with compromised immune systems.

Cannabis may accentuate the effects of HIV on the brain or perhaps may mitigate them because of its anti-inflammatory properties.

Ribó is the faculty advisor to new POCN Center for HIV Excellence that will provide information and resources to providers who may see relatively few patients with HIV.

‘Yes, PrEP is very important and very useful, but its use is complemented extremely by HIV treatment, so you really have to do both,’ says researcher.

Medicare Advantage plans have been associated with increased screening rates. But managed care tactics and narrow networks may be a disadvantage for people needing care.

A team of researchers studied 22 HIV 'post-treatment controllers' — people whose HIV infections are kept in check even after stopping antiretroviral therapy.

A Kaiser Permanente study shows a close link between HIV RNA levels and low CD4 counts and the risk of heart failure.

Stem cell transplants are not being proposed as treatments for HIV, but this case and a handful of others offer promising confirmation that HIV is not entirely incurable.

The known benefits of antiretroviral therapy (ART) in pregnant persons living with HIV outweigh the risks, which include low-birth weight and metabolic complications for the pregnant person, says the lead author of a review article ART and adverse outcomes published in the New England Journal of Medicine.

Researchers report positive result from a phase 1 trial that show the presence of the antiviral medication in rectal tissue.

Uptake of pre-exposure prophylaxis (PrEP) has been slow. A survey shows that safety and side effects are the top concerns.

Gastroesophageal reflux disease is a risk factor for what is now the more common type of esophageal cancer, adenocarcinoma. Immunotherapy is coming on strong as a treatment.

Tulane University researchers are studying whether dysregulation of the oral microbiome might affect HIV outcomes. They are using rhesus monkeys and SIV infection as a model.